Hussman Strategic Advisors Inc. Invests $2.79 Million in Exact Sciences Corporation $EXAS

Hussman Strategic Advisors Inc. bought a new stake in Exact Sciences Corporation (NASDAQ:EXAS) in the second quarter, HoldingsChannel.com reports. The institutional investor bought 52,500 shares of the medical research company’s stock, valued at approximately $2,790,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Larson Financial Group LLC increased its stake in Exact Sciences by 2,804.8% in the 1st quarter. Larson Financial Group LLC now owns 610 shares of the medical research company’s stock worth $26,000 after purchasing an additional 589 shares during the period. National Pension Service grew its holdings in shares of Exact Sciences by 75.1% in the first quarter. National Pension Service now owns 681 shares of the medical research company’s stock worth $29,000 after purchasing an additional 292 shares during the last quarter. SVB Wealth LLC purchased a new position in shares of Exact Sciences in the first quarter worth $30,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in Exact Sciences during the 1st quarter valued at $34,000. Finally, Banque Cantonale Vaudoise bought a new stake in Exact Sciences during the 1st quarter valued at $34,000. 88.82% of the stock is currently owned by institutional investors.

Insider Transactions at Exact Sciences

In related news, Director James Edward Doyle sold 2,000 shares of the business’s stock in a transaction dated Thursday, October 9th. The shares were sold at an average price of $60.00, for a total transaction of $120,000.00. Following the sale, the director owned 57,962 shares of the company’s stock, valued at $3,477,720. The trade was a 3.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.20% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on EXAS shares. Craig Hallum boosted their price objective on shares of Exact Sciences from $65.00 to $85.00 and gave the company a “buy” rating in a research report on Thursday, September 11th. Wells Fargo & Company set a $68.00 price target on Exact Sciences in a research report on Wednesday, October 1st. Royal Bank Of Canada reduced their target price on Exact Sciences from $54.00 to $46.00 and set a “sector perform” rating on the stock in a research note on Thursday, August 7th. Barclays raised their price target on Exact Sciences from $55.00 to $65.00 and gave the stock an “overweight” rating in a research note on Thursday, October 2nd. Finally, Evercore ISI boosted their price objective on shares of Exact Sciences from $64.00 to $68.00 and gave the company an “outperform” rating in a research report on Tuesday, October 7th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Exact Sciences currently has an average rating of “Moderate Buy” and an average target price of $68.90.

Exact Sciences Trading Up 3.5%

NASDAQ EXAS opened at $66.98 on Tuesday. The firm has a market capitalization of $12.68 billion, a PE ratio of -12.34, a P/E/G ratio of 5.56 and a beta of 1.24. The stock’s 50 day moving average is $56.38 and its 200 day moving average is $52.83. Exact Sciences Corporation has a twelve month low of $38.81 and a twelve month high of $72.83. The company has a quick ratio of 2.56, a current ratio of 2.89 and a debt-to-equity ratio of 0.94.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings data on Monday, November 3rd. The medical research company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.10 by $0.14. Exact Sciences had a negative return on equity of 1.75% and a negative net margin of 34.19%.The business had revenue of $850.74 million during the quarter, compared to analyst estimates of $810.42 million. During the same quarter last year, the firm posted ($0.21) earnings per share. The company’s revenue for the quarter was up 20.0% on a year-over-year basis. Exact Sciences has set its FY 2025 guidance at EPS. Research analysts forecast that Exact Sciences Corporation will post -0.58 earnings per share for the current fiscal year.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.